Stay updated on PD-L1+ NSCLC: Pembrolizumab vs Chemo Clinical Trial
Sign up to get notified when there's something new on the PD-L1+ NSCLC: Pembrolizumab vs Chemo Clinical Trial page.

Latest updates to the PD-L1+ NSCLC: Pembrolizumab vs Chemo Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision: v3.4.2 is displayed, replacing the previous v3.4.1. This appears to be a backend/UI maintenance update with no visible changes to study details, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check20 days agoChange DetectedMinor version update from Revision: v3.4.0 to v3.4.1 with no visible changes to core content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check27 days agoChange DetectedShow glossary and minor copy changes (including a Revision: v3.4.0 note and capitalization tweaks) were added; these changes do not affect study data or core functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision label on the page updated from v3.3.3 to v3.3.4.SummaryDifference0.1%

- Check63 days agoChange DetectedFooter now shows Revision: v3.3.3. The HHS Vulnerability Disclosure link and the previous Revision: v3.3.2 entry were removed.SummaryDifference0.1%

- Check92 days agoChange DetectedThe Publications section text was updated to clarify that publications are provided voluntarily by the person entering information about the study, and the revision label changed from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to PD-L1+ NSCLC: Pembrolizumab vs Chemo Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PD-L1+ NSCLC: Pembrolizumab vs Chemo Clinical Trial page.